Go to Bing homepage
Go to Bing homepage

(Reuters) - The proposed price for Spark Therapeutics Inc’s (ONCE.O) groundbreaking one-time gene therapy for a rare form of blindness is far too high, …
Reuters · 10d
The FDA’s approval of Luxturna, the first gene therapy to treat a specific inherited gene mutation, RPE65 – has been deemed a medical milestone. The …
Fox News · 9d
After decades of setbacks, gene therapy—a loosely defined umbrella term for any technique that uses genes to treat or prevent disease—is finally …
Wired News · 11d
(Reuters) - The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost …
Business Insider · 10d
Earlier this month, Spark Therapeutics announced that its gene therapy Luxturna, for a rare form of blindness, would cost $850,000 a year. The price …
Forbes · 9d
READ NEXT: Spark prices its gene therapy as most expensive U.S. medicine — but with plans to ease cost concerns ICER reached its suggested list …
PBS · 9d
The federal agency has approved the gene therapy Luxturna for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal …
The Daily Iowan · 1d